FDA Thaws Inspections Freeze
Executive Summary
The US agency tells Medtech Insight that it’s resuming domestic surveillance inspections “given the decline in COVID-19 cases across the country.”
You may also be interested in...
Inspection-Challenged FDA Defies Odds By Issuing Most Quality-Related Warning Letters Since 2017
US FDA data shared with Medtech Insight show that the number of quality-related warning letters sent to device manufacturers in calendar year 2021 ticked up 33% from 2020. Last year’s enforcement missives were also the most handed out by the agency in four years.
FDA Extends On-Site Surveillance Inspections Freeze Another 2 Weeks Because Of Omicron
The US agency had previously decided to halt domestic inspections through at least 19 January because of the COVID-19 Omicron variant. But now that timeline has been lengthened.
Speaking Of Medtech, Ep. 10: FDA’s TAP Pilot
In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?